Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 4/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18424173 | 0.77 | CYP1A2 (0.73) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL26042174 | 0.77 | CYP1A2 (0.69) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL19917154 | 0.76 | CYP1A2 (0.55) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25259084 | 0.76 | CYP1A2 (0.55) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL29082769 | 0.76 | CYP1A2 (0.80) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL20502052 | 0.76 | CYP1A2 (0.61) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL640619 | 0.76 | CYP1A2 (0.76) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25299888 | 0.75 | CYP1A2 (0.57) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL18986983 | 0.75 | CYP1A2 (0.54) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25261019 | 0.75 | CYP1A2 (0.60) | CYP1A2CYP2D6MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4308227-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396473-A | Imidazopyridinyl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK4 | CYP1A2 1976/4885CYP2D6 2667/4885MGLL 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.